Back to articles
Comparative guide · 6 min read

Lutein vs Zeaxanthin — the two macular pigment carotenoids

Updated 2026-05-12 · Reviewed by SupplementScore editors · No sponsorships

Lutein and zeaxanthin are the two xanthophyll carotenoids that, together with meso-zeaxanthin, form the yellow macular pigment of the retina. They aren't really competitors — they're partners. The AREDS2 trial that established the modern eye-supplement formula used a fixed 10 mg lutein + 2 mg zeaxanthin combination, and that ratio is what the clinical evidence base is built on. The relevant questions are: should you supplement at all? Is the 5:1 ratio right? And what does choosing one over the other actually buy?

Quick verdict

GoalBetter choiceWhy
Slowing progression of intermediate-stage AMD Both, in AREDS2-style combination AREDS2 used 10 mg lutein + 2 mg zeaxanthin within a larger formula; that's the studied combination.
Raising macular pigment optical density (MPOD) Both — additive Lutein dominates the peripheral macula; zeaxanthin (and meso-zeaxanthin) dominates the central fovea.
Visual function in healthy eyes (contrast, glare recovery) Both — modest evidence Some trials show small improvements in glare disability and contrast sensitivity with combined dosing.
Cognitive endpoints (some signal in older adults) Lutein-dominant (current trials) Most cognitive-aging trials use lutein-dominant blends; small effects on processing speed.
Primary prevention in users with no AMD risk factors Neither — focus on diet Leafy greens, eggs, and corn provide adequate intake; supplements add little above food.
Smokers AREDS2 (which excluded beta-carotene specifically) Beta-carotene increased lung cancer risk in smokers — AREDS2 swapped it for lutein/zeaxanthin.

How they compare on biology

Spatial distribution in the retina

Lutein is distributed across the broader macula and contributes much of the peripheral macular pigment. Zeaxanthin concentrates in the central fovea (the highest-acuity zone of the retina), and its isomer meso-zeaxanthin is found almost exclusively there. The ratio of lutein to zeaxanthin in dietary intake is roughly 5:1; the ratio in the central fovea is closer to 1:2 in favour of zeaxanthin. Some formulators argue this supports zeaxanthin- or meso-zeaxanthin-enriched supplements, but the AREDS2 trial used the 5:1 ratio and is the strongest clinical evidence base — replication of any "fovea-targeted" formula at clinical AMD-progression endpoints has not been shown.

What AREDS2 actually showed

The Age-Related Eye Disease Study 2 (AREDS2, n≈4,200) tested adding lutein 10 mg + zeaxanthin 2 mg to the original AREDS formula (and removing beta-carotene). Headline finding: in users with intermediate AMD, the lutein/zeaxanthin-containing formula reduced progression to advanced AMD by approximately 10% relative to the original AREDS formula. In a substudy of users with the lowest baseline dietary lutein/zeaxanthin intake, the reduction was larger (~25%). The trial did not show benefit in users without intermediate AMD, in early AMD, or as primary prevention. The takeaway: this is a stage-specific intervention, not a "preserve eye health" general supplement.

Diet vs supplement intake

Spinach, kale, collard greens, and broccoli are high-lutein foods. Egg yolks have excellent bioavailability because the yolk fat improves absorption. Yellow corn and bell peppers contribute zeaxanthin specifically. Typical Western diet intake is 1–2 mg/day combined; trial-level doses (10 mg lutein + 2 mg zeaxanthin) represent 5–10× that. For users with low dietary intake, the supplement gap matters; for users eating leafy greens regularly with adequate fat for absorption, the supplement may add little.

Bioavailability and form

Both are fat-soluble carotenoids — must be taken with a meal containing fat. Lutein from supplements is typically derived from marigold flowers. Free lutein is more bioavailable than lutein esters; most modern supplements use the free form. Zeaxanthin is more often supplied as zeaxanthin RR-isomer plus meso-zeaxanthin in branded supplements. Storage matters — both oxidise; opaque packaging and reasonable shelf-life turnover are appropriate.

Practical rule. Don't pick one. The clinical evidence base is built on the AREDS2 combination (10 mg lutein + 2 mg zeaxanthin), and that's the dose-form to anchor on if you're supplementing for AMD prevention in intermediate-stage disease. For early AMD, primary prevention, or general "eye health," diet (leafy greens with egg or olive oil) is the higher-leverage intervention. Stand-alone lutein or stand-alone zeaxanthin both have less clinical evidence than the combination.

Who should consider supplementing

Users with intermediate-stage AMD (drusen, pigment changes) following ophthalmologist guidance — the AREDS2 formula is the indication. Older adults with very low dietary leafy-green intake — supplementation may help close the gap. Smokers with eye-health concerns — note that beta-carotene-containing eye formulas should be avoided due to lung cancer risk; AREDS2 removed beta-carotene specifically for this reason.

Who should skip

Healthy adults with adequate dietary intake — the absolute benefit is small and not well-established outside intermediate AMD. Users with early AMD — the AREDS2 evidence doesn't extend to this stage. Users buying generic "macular support" formulas that bundle lutein/zeaxanthin with bilberry, eyebright, and other unproven ingredients — pay for the active ingredients only.

Safety

Both are generally well-tolerated. High intake of supplemental lutein (≥15 mg/day) can cause carotenoderma — a harmless yellowing of the skin that reverses with reduced intake. Theoretical concerns about increased lung cancer risk that affected beta-carotene supplementation in smokers don't appear to extend to lutein/zeaxanthin, but caution at high doses in this population is reasonable. Pregnancy and lactation: dietary intake is fine; specific supplementation should be discussed with prescriber.

What the price difference buys you

AREDS2 formulas (lutein 10 mg + zeaxanthin 2 mg + vitamin C 500 mg + vitamin E 400 IU + zinc 80 mg + copper 2 mg) run $20–35/month at mid-market. Stand-alone lutein 10 mg runs $5–12/month; stand-alone zeaxanthin 2–10 mg runs $10–20/month. Buying the AREDS2 combination is more cost-effective than assembling components separately if you're targeting the AMD-progression indication.

What we'd actually buy

For intermediate AMD (with ophthalmologist guidance): a verified AREDS2 formula (e.g., PreserVision AREDS2 or equivalent), at the studied doses. Generic versions are acceptable if they hit the same dose targets.

For general eye health and no AMD: leafy greens 1–2 cups/day, egg yolks 2–4×/week, regular ophthalmologist screening, UV-protective sunglasses outdoors. Skip the dedicated eye supplement.

Sources

Read more: